A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires
- PMID: 28925027
- PMCID: PMC5858989
- DOI: 10.1002/cpt.885
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires
Corrected and republished in
-
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.Clin Pharmacol Ther. 2019 Aug;106(2):374-382. doi: 10.1002/cpt.1194. Epub 2018 Sep 2. Clin Pharmacol Ther. 2019. PMID: 30079582
Abstract
Nonadherence to treatment is a major cause of lupus flares. Hydroxychloroquine (HCQ), a major medication in systemic lupus erythematosus, has a long half-life and can be quantified by high-performance liquid chromatography. This international study evaluated nonadherence in 305 lupus patients with flares using drug levels (HCQ <200 ng/ml or undetectable desethylchloroquine), and self-administered questionnaires (MASRI <80% or MMAS-8 <6). Drug levels defined 18.4% of the patients as severely nonadherent. In multivariate analyses, younger age, nonuse of steroids, higher body mass index, and unemployment were associated with nonadherence by drug level. Questionnaires classified 39.9% of patients as nonadherent. Correlations between adherence measured by questionnaires, drug level, and physician assessment were moderate. Both methods probably measured two different patterns of nonadherence: self-administered questionnaires mostly captured relatively infrequently missed tablets, while drug levels identified severe nonadherence (i.e., interruption or erratic tablet intake). The frequency with which physicians miss nonadherence, together with underreporting by patients, suggests that therapeutic drug monitoring is useful in this setting. (Trial registration: ClinicalTrials.gov: NCT01509989.).
© 2017 American Society for Clinical Pharmacology and Therapeutics.
Conflict of interest statement
Figures

Similar articles
-
A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.Clin Pharmacol Ther. 2019 Aug;106(2):374-382. doi: 10.1002/cpt.1194. Epub 2018 Sep 2. Clin Pharmacol Ther. 2019. PMID: 30079582
-
Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting.Arthritis Rheum. 2007 Aug 15;57(6):1000-6. doi: 10.1002/art.22898. Arthritis Rheum. 2007. PMID: 17665465
-
Development and Initial Validation of a Systemic Lupus Erythematosus-Specific Measure of the Extent of and Reasons for Medication Nonadherence.J Rheumatol. 2022 Dec;49(12):1341-1348. doi: 10.3899/jrheum.220399. Epub 2022 Sep 1. J Rheumatol. 2022. PMID: 36243406 Free PMC article.
-
Adherence to treatment in systemic lupus erythematosus patients.Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329-40. doi: 10.1016/j.berh.2013.07.001. Best Pract Res Clin Rheumatol. 2013. PMID: 24238690 Review.
-
Hydroxychloroquine: a multifaceted treatment in lupus.Presse Med. 2014 Jun;43(6 Pt 2):e167-80. doi: 10.1016/j.lpm.2014.03.007. Epub 2014 May 19. Presse Med. 2014. PMID: 24855048 Review.
Cited by
-
Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.Rheumatology (Oxford). 2020 Dec 1;59(12):3807-3816. doi: 10.1093/rheumatology/keaa157. Rheumatology (Oxford). 2020. PMID: 32442312 Free PMC article.
-
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data.Lupus Sci Med. 2022 Mar;9(1):e000651. doi: 10.1136/lupus-2021-000651. Lupus Sci Med. 2022. PMID: 35318256 Free PMC article.
-
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development.Lupus Sci Med. 2022 Aug;9(1):e000720. doi: 10.1136/lupus-2022-000720. Lupus Sci Med. 2022. PMID: 35914839 Free PMC article.
-
Therapeutic Hydroxychloroquine Blood Levels Are Associated With Fewer Hospitalizations and Possible Reduction of Health Disparities in Lupus.Arthritis Care Res (Hoboken). 2024 Dec;76(12):1606-1616. doi: 10.1002/acr.25422. Epub 2024 Oct 1. Arthritis Care Res (Hoboken). 2024. PMID: 39187461 Free PMC article.
-
Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases.Clin Pharmacokinet. 2019 Apr;58(4):525-533. doi: 10.1007/s40262-018-0712-z. Clin Pharmacokinet. 2019. PMID: 30255310 Free PMC article.
References
-
- Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939. - PubMed
-
- Costedoat-Chalumeau N, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013;27:329–340. - PubMed
-
- Costedoat-Chalumeau N, Amoura Z, Hulot JS, Lechat P, Piette JC. Hydroxychloroquine in systemic lupus erythematosus. Lancet. 2007;369:1257–1258. - PubMed
-
- Costedoat-Chalumeau N, Leroux G, Piette J-C, Amoura Z. Antimalarials and systemic lupus erythematosus. In: Lahita RG, Tsokos G, Buyon JP, Koike T, editors. Systemic lupus erythematosus. 5. Elsevier; 2010. pp. 1061–81.
-
- Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69:20–28. - PubMed
Publication types
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical